Pfizer raises 2026 guidance as third-quarter revenue holds near $16.6 billion

what happened

Pfizer reported third-quarter 2026 revenue of $16.583 billion, compared with $16.654 billion a year earlier, so sales were roughly flat on an operational basis. Adjusted diluted EPS came in at $0.87, unchanged from the prior-year quarter, while reported net income fell 8% to $3.242 billion. TradingView cited the company's financial results in reporting these figures.

The company raised its full-year 2026 revenue guidance to $62.0–64.0 billion, a $1.5 billion increase at the midpoint. Adjusted diluted EPS guidance was narrowed to $2.95–3.05 from $2.80–3.00. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally, and launched and acquired products rose 32%.

why it matters

Lower demand for COVID-19 products weighed on sales, but gains from Eliquis and newer medicines offset part of the drop. A higher outlook usually supports large drugmakers' shares, though investors will look to upcoming quarters to judge how durable the growth is.

market impact

Pfizer and pharma shares: raised outlook supports the company's stock

• ▲Pfizer shares (PFE) pressure up — a higher revenue and profit outlook improves expectations for the company

tags

instruments